- Akoya Biosciences Reports First Quarter 2024 Financial Results
- Akoya Biosciences and NeraCare Enter into an Exclusive Agreement to Enable Personalized Therapy Selection for Early-Stage Melanoma Patients
- Akoya Biosciences Opens Operations and Manufacturing Center of Excellence in Marlborough, Massachusetts
- Akoya Biosciences and Shanghai KR Pharmtech Announce Chinese Regulatory Agency Premarket Approval for KR-HT5 in China to Support Next Generation Pathology Clinical Workflows
- Akoya to Report First Quarter 2024 Financial Results on May 13th, 2024
- Akoya Biosciences Showcases Spatial Biology 2.0 Solutions at AACR Annual Meeting with Case Studies Demonstrating Unprecedented Speed and Scale
- Akoya Reports Record Revenue in the Fourth Quarter of 2023 and Provides Full Year 2024 Financial Outlook
- Akoya to Report Fourth Quarter and Full Year 2023 Financial Results on March 4th, 2024 and Participate at an Upcoming Investor Conference
- Akoya Biosciences’ Technology Enables Queensland Spatial Biology Centre to Revolutionize the Diagnosis and Treatment of Cancer and Other Diseases
- Akoya Biosciences Announces that Garry Nolan, Ph.D., James Allison, Ph.D., and Padmanee Sharma, M.D., Ph.D., Join Newly Created Scientific Advisory Board
More ▼
Key statistics
On Wednesday, Akoya Biosciences Inc (AKYA:NSQ) closed at 2.13, 13.30% above the 52 week low of 1.88 set on May 23, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.21 |
---|---|
High | 2.21 |
Low | 2.10 |
Bid | 1.87 |
Offer | 2.60 |
Previous close | 2.13 |
Average volume | 340.49k |
---|---|
Shares outstanding | 49.39m |
Free float | 26.09m |
P/E (TTM) | -- |
Market cap | 105.19m USD |
EPS (TTM) | -1.47 USD |
Data delayed at least 15 minutes, as of Jul 03 2024 18:00 BST.
More ▼